Cardiol Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead product consist CardiolRx(TM). Cardiol Therapeutics Inc. is based in Oakville, ON.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-26.77M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 9.78 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -209.63% |
| Return on Assets (Trailing 12 Months) | -141.09% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.26 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.26 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.01 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.22 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.07 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.37 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.34 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 82.65M |
| Free Float | 78.31M |
| Market Capitalization | $119.84M |
| Average Volume (Last 20 Days) | 0.24M |
| Beta (Past 60 Months) | 1.03 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.25% |
| Percentage Held By Institutions (Latest 13F Reports) | 12.49% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |